CClinicalTrials.gg
RecruitingNCT07431099RECOLOR-HNUpdated May 29, 2026

Skin Color Matching in Head and Neck Reconstructive Surgery

An interventional study of RECELL® Autologous Cell Harvesting Device in Head and Neck Cancer and Head and Neck Trauma, sponsored by Yale University. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Yale University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study will examine whether cutaneous reconstruction with RECELL® atop de-epithelialized tissue provides better skin color matching than standard grafting methods. The goal is to compare color match, healing, and patient satisfaction across three reconstruction techniques. Color matching will be assessed using colorimeter-based ΔE00 measurements at set postoperative intervals. All patients will receive the same intervention.

Read the detailed description

Patients with head and neck cutaneous defects requiring skin grafting for reconstruction will have their wound bed divided into three sections: (1) split-thickness skin graft, (2) de-epithelialized tissue, (3) de-epithelialized tissue + RECELL® ASCS. Color matching will be determined via a handheld colorimeter and calculated using the CIEDE2000 color difference formula. Healing, morbidity, and patient satisfaction outcomes will be assessed at interval post-operative clinic visits. Intervention is administered on day of surgery. Following surgery, participants return for postoperative assessments at Day 14 and months 1, 3, and 6, during which clinical wound evaluations and adverse event checks are performed and color match is measured.

The primary objective of this study will be to assess whether RECELL® Autologous Skin Cell Suspension in conjunction with de-epithelialized tissue will provide superior color matching compared to de-epithelialized tissue alone or split-thickness skin grafting.

Secondary objectives include assessment of healing, morbidity, and patient-reported satisfaction with their skin grafting results.

02

Conditions studied

  • Head and Neck Cancer
  • Head and Neck Trauma

Keywords

  • Head and neck cutaneous defects
  • Head and neck reconstructive surgery
03

In context

Head and Neck Neoplasms

2,344 studies on the registry are indexed under Head and Neck Neoplasms; 552 are open to participants now.

This study's planned enrollment of 20 is below the median of 47 across 1,751 interventional studies indexed under Head and Neck Neoplasms.

Browse Head and Neck Neoplasms studies →

Lead sponsor

Yale University is the lead sponsor of 1,724 studies on the registry; 298 are open to participants now.

Of its 210 completed or terminated interventional studies of FDA-regulated products, 126 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Provision of signed and dated informed consent form
  • Ability to understand and respond to patient-reported outcome measures in English
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Subjects aged ≥18 may be included, provided they or their legal guardian are able to provide informed consent or assent in accordance with institutional policies
  • Is deemed a suitable candidate for head and neck reconstructive surgery, the basis of which will be determined by the surgeon performing the procedure as well as pre-operative assessment by the anesthesiology team
  • Possessing a cutaneous defect of a size, location, and depth deemed appropriate for either split-thickness skin grafting or de-epithelialized tissue reconstruction, as assessed preoperatively and/or intraoperatively by the surgical team
  • Reconstruction must occur within a clinically appropriate window following defect creation (e.g., immediate or delayed reconstruction within 14 days), depending on institutional protocol and wound status
  • Ability to adhere to post-operative discharge wound care instructions
  • Subjects must have reliable means of attending scheduled follow-up visits for outcome assessments (in person or via telemedicine if permitted)
  • Willingness to allow standardized clinical photographs of the surgical site to be taken and used for outcome analysis and potential publication

Exclusion criteria

Exclusion Criteria:

  • Member of one or more of the following vulnerable populations:

    • Children/under the age of 18: Aesthetic outcomes and satisfaction measures, such as those used in this study (e.g., FACE-Q), are not validated in children and may not yield reliable or interpretable results.
    • Pregnant/lactating individuals: Pregnant and lactating individuals are excluded due to the lack of safety data on RECELL® administration during pregnancy or breastfeeding.
    • Incarcerated individuals: The ability to provide fully voluntary and uncoerced consent may be compromised in correctional settings. Furthermore, consistent post-operative follow-up and outcome assessments, critical to the integrity of the study, may not be feasible due to restrictions on transportation, communication, and continuity of care.
    • Cognitively impaired individuals: Cognitively impaired individuals are excluded because they may lack the capacity to provide fully informed consent. Given that study participation involves outcome assessments (e.g., satisfaction surveys), full comprehension and participation are essential, and surrogate consent is not appropriate for this study.
  • Inability to tolerate general anesthesia, or any other circumstance that would render the subject unable to undergo surgical repair of their cutaneous defect
  • Known allergy or hypersensitivity to porcine-derived products or trypsin, which is used in the enzymatic preparation of the RECELL® autologous skin cell suspension
  • Subjects with known severe immunosuppression, poorly controlled diabetes, or other systemic conditions that could impair wound healing or increase infection risk
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Participants with head and neck cutaneous defect needing skin grafting

    Participants with cutaneous defects of the head and neck requiring skin grafting will have their defect split into three sections and closed with one of the following: (1) split-thickness skin graft (STSG), (2) de-epithelialized tissue alone, or (3) de-epithelialized tissue with RECELL® ASCS. All participants will receive the same intervention and will serve as their own controls. STSG and de-epithelialized tissue alone are each currently used standards of care.

    Device: RECELL® Autologous Cell Harvesting Device

Interventions

  • DeviceRECELL® Autologous Cell Harvesting Device

    RECELL Autologous Skin Cell Suspension (ASCS) will be used for color match and healing.

06

What researchers measure

Primary outcomes

  1. Color match at the reconstruction site

    Color match is measured with a handheld colorimeter using ΔE00 color difference formula. Values will be computed from these data to quantify skin color match with lower scores indicating closer match. Score range 0-5.

    Time frame: Postoperative assessments at Day 14 and months 1, 3, and 6

Secondary outcomes

  1. FACE-Q patient satisfaction questionnaire

    FACE-Q is a patient-reported outcome questionnaire for facial aesthetics with a total score range of 0-100 that measure satisfaction with appearance, quality of life, and procedure. Higher scores indicating better outcomes.

    Time frame: Month 3 and 6

  2. Mean healing time

    Healing time in days of both the graft recipient and donor sites

    Time frame: Postoperative assessments at Day 14 and months 1, 3, and 6

07

Study locations

3 of 3 sites recruiting
  • Shoreline Surgery Center
    Guilford, Connecticut 06437, United States
    Recruiting
  • Yale Milford Otolaryngology Clinic
    Milford, Connecticut 06460, United States
    Recruiting
  • Yale New Haven Hospital
    New Haven, Connecticut 06520, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07431099
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
May 20, 2026
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
May 29, 2026

Study contacts

Stanley Kusaka, BS
Contact
stanley.kusaka@yale.edu
971-325-8502
Suresh Mohan, MD
Contact
suresh.mohan@yale.edu
203-260-4622
Suresh Mohan, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion